PRODUCTION OF AN ACELLULAR PERTUSSIS VACCINE (TOXOID)

NICHD正在继续其对NICHD无细胞百日咳的评估 百日咳类毒素与白喉和 破伤风类毒素，导致三价DTP疫苗。被引用的 合同正在修改，以包括这种三价药物的开发 瑞典和美国临床试验中用于疗效测试的产品。 AMVAX已经提交了一份提案，要求继续生产 百日咳类毒素及其与购买的白喉和 破伤风类毒素。NICHD的代表(包括主任、 NICHD)审查了承包商在 散装百日咳类毒素的研制。已经确定AMVAX 将在#年前向NICHD提供0.7克联合散装DTP疫苗 1990年11月1日，另加1.0克散装DTP疫苗 1991年1月31日前交付。

The NICHD is continuing its evaluation of the NICHD acellular pertussis toxoid through combination of the pertussis toxoid with diphtheria and tetanus toxoids, resulting in a trivalent, DTP, vaccine. The referenced contract is being modified to include the development of this trivalent product for efficacy testing in clinical trials in Sweden and the U.S. AMVAX has submitted a proposal for the continued production of the pertussis toxoid, and its combination with purchased diphtheria and tetanus toxoids. Representatives of the NICHD (including the Director, NICHD) have reviewed the progress that the contractor has made in the development of a bulk pertussis toxoid. It has been determined that AMVAX shall supply the NICHD with 0.7 grams of the combined bulk DTP vaccine by November 1, 1990, and an additional 1.0 gram of the bulk DTP vaccine to be delivered by January 31, 1991.